Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Definitions

• the present invention relates to, inter alia, methods of treatment and combinations of (/?)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid
• Compound 1 useful for the treatment of primary biliary cholangitis (PBC).
• the methods further comprise administering Compound 1 , or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a compound selected from the group consisting of: an antihistamine
• PBC primary biliary cholangitis
• the sphingosine-1 -phosphate (SIP) receptors 1-5 constitute a family of G protein-coupled receptors with a seven-transmembrane domain. These receptors, referred to as SIPi to S IP5 (formerly termed endothelial differentiation gene (EDG) receptor-1 , -5, -3, -6, and -8, respectively; Chun et al., Pharmacological Reviews, 54:265-269, 2002), are activated via binding by sphingosine-1 -phosphate, which is produced by the sphingosine kinase-catalyzed phosphorylation of sphingosine.
• SIPi to S IP5 (formerly termed endothelial differentiation gene (EDG) receptor-1 , -5, -3, -6, and -8, respectively; Chun et al., Pharmacological Reviews, 54:265-269, 2002)
• S IPi, S IP4, and S IP5 receptors activate Gi but not Gq, whereas S IP2 and S IP3 receptors activate both Gi and Gq.
• Compound 1 The compound (R)-2-(7-(4-cyciopentyl-3-(trifluoromethyl)benzyloxy)-l , 2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) is a potent (EC50 cAMP, 0.093 nM (human)) and selective (EC50 ⁇ -arrestin, 6.10 nM (S IP,), >10,000 nM (S1P 2 ), >10,000 nM, (S 1P 3 ), 147 nM (S IP4), and 24.4 nM (S IP5)), orally available investigational drug candidate for the S IPi receptor.
• EC50 cAMP 0.093 nM (human)
• EC50 ⁇ -arrestin 6.10 nM (S IP,), >10,000 nM (S1P 2 ), >10,000 nM, (S 1P 3 ), 147 nM (S IP4), and 2
• Compound 1 showed calculated lymphocyte lowering IC50 values in four different species: 0.101 uM (mouse), 0.051 ⁇ (rat), 0.058 ⁇ (dog), and 0.098 ⁇ (monkey). Notably, the calculated lymphocyte lowering IC50 values reflect total plasma concentration wherein Compound 1 is highly protein bound (97.8% human, 98.0% rat). Compound 1 was shown to be efficacious in the murine experimental autoimmune encephalomyelitis (EAE) model that mimics multiple sclerosis.
• EAE murine experimental autoimmune encephalomyelitis
• Compound 1 prevented the onset and severity of disease relative to vehicle up to day 25, at which time dosing was discontinued. All treatment arms went on to develop severe disease.
• Compound 1 was also examined. Treatment began at day 18, by which time all animals had developed severe disease. Compound 1 was administered from day 18 to day 37 and showed to reverse the disease relative to vehicle and was similar to the efficacy observed with fingolimod (i.e., GILENYA® was approved in September 2010 for the treatment of individuals with relapsing forms of multiple sclerosis). Similarly, Compound 1 was efficacious in a collagen induced arthritis (CIA) model. Prophylactic oral administration in female Lewis rats resulted in a significant reduction in ankle diameters on day 17 following a daily oral dose and was similar to that observed in rats treated with fingolimod or methotrexate.
• CIA collagen induced arthritis
• S IP is a signaling sphingolipid required by lymphocytes to exit the lymphoid tissue and enter the bloodstream via a chemotactic gradient.
• the S 1P1 receptor is a physiological mediator which has been shown to regulate lymphocyte recirculation between lymphoid tissue and blood. Binding and
• SI PI receptor internalization of the SI PI receptor may result in lymphocyte retention within lymphoid tissue, with subsequent reduction in peripheral lymphocyte count and lymphocyte availability for recruitment to sites of inflammation.
• S1P1 receptor surface expression is required for SIP gradient-mediated lymphocyte migration out of lymphoid tissue into the circulation (Brinkmann V., Nat Rev Drug Discov 2010 November, 9(1 1):883-97).
• Primary biliary cholangitis is a chronic cholestatic liver disease of unknown cause. Progressive bile-duct injury from portal and periportal inflammation may result in progressive fibrosis and eventual cirrhosis.
• Immunohistochemical staining of T lymphocytes in portal and periportal areas in PBC patients shows CD4-positive and CD8-positive T cells (T-cell populations known to be modulated by S1P1 interaction).
• T-cell populations known to be modulated by S1P1 interaction
• natural killer cells also appear to play a role in PBC. Resting as well as activated NK cells express S 1P1 , S 1P4, and S 1P5 receptors. The S1P5 receptor has been reported to be involved in chemotaxis of NK cells (Jenne et al 2009).
• mice that lacked both S IP lyase and S 1P4 (Sgpl l-/- Slpr4-/-) had significantly lower blood neutrophil counts and serum pro-inflammatory cytokines than the single-mutant Sgpll-/-mice (Allende et al. 2011).
• S1P4 receptor in neutrophil trafficking, which may be relevant given reports suggesting a role for EL- 33 in enhancing the migration of neutrophils in the progression PBC (Sun et al. 2014).
• Avoidance of S1P2 interaction is important due to the reported links between S 1P2 modulation in cholangiocarcinoma (CCA), possibly driven by conjugated bile acid modulation of the S 1P2 receptor on cholangiocytes (Liu et al 2014). Inhibition of SlPl, but not S 1P2 receptors, has been shown to reduce bile salt (glycochenodeoxycholic acid)-induced apoptosis in rat hepatocytes, indicating potential therapeutic benefits in PBC (Karimian et al., Biochim Biophys Acta. 2013 Dec; 1832(12): 1922-9).
• CCA cholangiocarcinoma
• Modulation of the S lPl, S 1P4, and S 1P5 receptors therefore represents a target profile for treating PBC.
• liver enzyme elevation has been seen for GILENYA (fingolimod), siponimod, ponesimod, GSK2018682, and ozanimod (Gergely et al., British J ofPharm 2012; 167: 1035-1047; D'Ambrosio et al., Therapeutic Advances in Chronic Disease 2016; 7(l): 18-33; Cohen et al., 32 nd Congress of ECTRIMS 2016 Sep 14-17; Xu et al., Am College of Clinical Pharm 2014; 3(3): 170-178).
• the product label for GILENYA (fingolimod) contain warnings and precautions about hepatic effects.
• pathophysiological evidence of a reduction in drug metabolizing enzyme activities in patients with PBC, along with general liver impairment effects (as evidenced by elevated liver transaminases) (Reshetnyak, World J of Gastroenterology 2015 July 7; 21(25):7683-7708).
• the safety of a S IP modulator in a patient population with impaired liver function is unknown.
• Compound 1 shows an overall selective activation of S lPl , S 1P4, and S 1P5 and the potential for 3afc administration to individuals with liver impairment, and thus represents a much needed option for the treatment of individuals with PBC.
• (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l , 2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically salt, solvate, or hydrate thereof.
• primary biliary cholangitis PBC is primary biliary cirrhosis.
• the present invention is directed to uses of (/?)-2-(7-(4-cyclopentyl-3- (tiifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in the manufacture of a medicament for the treatment of primary biliary cholangitis (PBC).
• PBC primary biliary cholangitis
• the individual was previously treated with a therapeutically effective amount of ursodeoxycholic acid (UDCA).
• UDCA ursodeoxycholic acid
• the individual is currently treated with a therapeutically effective amount of ursodeoxycholic acid (UDCA).
• UDCA ursodeoxycholic acid
• the therapeutically effective amount of UDCA is substantially the same amount (stable dose) for at least 6 months.
• the therapeutically effective amount of UDCA is substantially the same amount (stable dose) for at least 3 months.
• the individual was previously treated with ursodeoxycholic acid (UDCA) and the individual had an inadequate response to UDCA.
• UDCA ursodeoxycholic acid
• the individual had an inadequate response to UDCA as determined by an alkaline phosphate.
• ALP alkaline phosphate
• UPN upper limit of normal
• the individual had an inadequate response after 6 months of treatment with UDCA.
• the individual had an inadequate response after 6 months of treatment with UDCA and an alkaline phosphate (ALP) > 1.67 x upper limit of normal (ULN).
• ALP alkaline phosphate
• the treatment dose of UDCA was at least 13 mg/kg/day.
• the individual has at least one primary biliary cholangitis diagnosis criteria selected from the group consisting of:
• AMA anti-mitochondrial antibody
• the individual has at least two primary biliary cholangitis diagnosis criteria selected from the group consisting of:
• AMA anti-mitochondrial antibody
• the individual has at least one of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• the individual has at least one of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• the individual has at least one additional condition selected from the group consisting of: pruritus, fatigue, osteoporosis, vitamin deficiencies, dry eyes and/or mouth, portal hypertension, and pain.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is formulated as a capsule or tablet suitable for oral administration.
• the individual is administered a titration dose of Compound 1 prior to the administering the therapeutically effective amount of Compound 1, wherein the titration dose is less than the therapeutically effective amount of Compound 1.
• the titration dose is less than about 2 mg of Compound 1.
• the titration dose is maintained until there are no significant changes in vital signs and/or RKG of the individual.
• the titration dose is maintained until the pulse rate > 55 bpm, systolic blood pressure (SBP) > 90, and diastolic blood pressure (DBP) > 55 mrnHg in the individual.
• the titration dose is maintained for no more than 14 days prior to administering the therapeutically effective amount of Compound 1.
• the titration dose comprises a first titration dose and a second titration dose, wherein the first titration dose is less than the second titration dose and each titration dose is less than the therapeutically effective amount of Compound 1.
• the first titration dose is in an amount equivalent to about 1 mg of Compound 1.
• the second titration dose is in an amount equivalent to about 1.5 mg of Compound 1.
• the first titration dose is in an amount equivalent to about 1 mg of Compound 1 and the second titration dose is in an amount equivalent to about 1.5 mg of Compound 1.
• the first titration dose is maintained for no more than 7 days prior to administering the second titration dose.
• the second titration dose is maintained for no more than 7 days prior to administering the therapeutically effective amount of Compound 1.
• the therapeutically effective amount of Compound 1 or a
• the therapeutically effective amount of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is in an amount equivalent to about 2 mg of Compound 1.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is selected from: Compound 1 , a calcium salt of Compound 1 , and an L-arginine salt of
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is an L-arginine salt of Compound 1.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is an anhydrous, non-sol vated crystalline form of the L-arginine salt of Compound 1.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is a crystalline free-plate habit of the non-solvated L-arginine salt of Compound 1.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is an anhydrous, non-solvated crystalline form of Compound 1.
• the method further comprises administering Compound 1 , or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a therapeutically effective amount of with a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and/or vitamin D supplement, and vitamin A, D, E and/or K supplement.
• a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and/or vitamin D supplement, and vitamin A, D, E and/or K supplement.
• Some embodiments of the present invention related to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC), wherein the medication is (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically salt, solvate, or hydrate thereof, the package comprising:
• a first number of daily units of a pharmaceutical composition comprising one or more doses of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein each dose is in an amount equivalent to about 1.5 mg or less of Compound 1 , and
• a second number of daily units of a pharmaceutical composition comprising a standard dose of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is in an amount equivalent to about 1.0 to about 2.5 mg of Compound 1.
• the dose of the first number of daily units is in an amount equivalent to about 1 mg of Compound 1.
• the dose of the first number of daily units is in an amount equivalent to about 1.5 mg of Compound 1. In some embodiments, the dose of the second number of daily units is in an amount equivalent to about 2 mg of Compound 1.
• the dose of the first number of daily units is in an amount equivalent to about 1 mg or 1.5 mg of Compound land the dose of the second number of daily units is in an amount equivalent to about 2 mg of Compound 1.
• kits comprising a titration package according to any previous embodiment, and instructions indicating that the medication is to be administered to an individual in need of treatment, of primary biliary cholangitis (PBC).
• PBC primary biliary cholangitis
• Figure 1 shows a PXRD Pattern overlay for the L-arginine salt of Compound 1 showing the peak intensity differences between plates and spherulitcs indicating a higher degree of crystallinity for the plates compared to the spherulites. Also shown is the lower sample-related background scatter (i.e., a lower amorphous halo contribution) for the plates. However, the plates and spherulites are observed to show the same crystal phase.
• Figure 2 shows a schedule of procedures and visits for screening, treatment, and follow-up periods for individuals related to the clinical study described in Example 2.
• Figure 3 shows a schedule of procedures and visits for the screening period for individuals related to the clinical study described in Example 2.
• Figure 4 shows a schedule of procedures and visits for the treatment period (Part 1) for individuals related to the clinical study described in Example 2.
• Figure 5 shows a schedule of procedures and visits for the treatment period (Part 2) for individuals related to the clinical study described in Example 2.
• Figure 6 shows a schedule of procedures and visits for the follow-up period for individuals related to the clinical study described in Example 2.
• Figure 7 shows a flowchart for the preparation of core tablets of the L-arginine salt of (R)-2-(7- (4- y lopentyl-3-(trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid
• AE adverse event
• ALP alkaline phosphatase
• C4 7 alpha-hydroxy-4-cholesten-3-one
• ECG electrocardiogram
• EOS end of study
• EOT end of treatment
• EWD early withdrawal
• FU follow up
• HBsAg hepatitis B surface antigen
• HCV hepatitis C virus
• HIV human immunodeficiency virus
• PK pharmacokinetics
• PML progressive multifocal leukoencephalopathy
• pSS primary Sjogren's syndrome
• TB tuberculosis.
• PK samples for PK will be collected at up to 45 min pre-dose, and at 2, 4, 6, and 8 hours post-dose for Day 1 and Week 2, and optionally at 12 and/or 24 hours post-dose at Week 2.
• Week 12 If a patient does not dose escalate, a pre-dose sample will be taken. If a patient dose escalates to 2 mg daily dose, a pre-dose, 6- and 8-hour post-dose sample will be collected.
• Week 14 If a patient is on a 2 mg daily dose a pre-dose and 2, 4, 6, 8, and optional 12 and/or 24 hour post-dose sample will be collected.
• Week 24 all patients will have a PK sample collected approximately 24 hours after their last dose during the Week 24 visit with 2 optional timepoints between 72 hours and 1 week after their last dose. Day 1 and Week 2 data will provide guidance for potential dose escalation of etrasimod at week 12.
• AE adverse event
• ALP alkaline phosphatase
• C4 7 alpha-hydroxy-4-cholesten-3-one
• ECG electrocardiogram
• EOS end of study
• EOT end of treatment
• EWD early withdrawal
• FU follow up
• HBsAg hepatitis B surface antigen
• HCV hepatitis C virus
• HIV human immunodeficiency virus
• PK pharmacokinetics
• PML progressive multifocal leukoencephalopathy
• pSS primary Sjogren's syndrome
• TB tuberculosis.
• the present disclosure provides, inter alia, methods of treating primary biliary cholangitis (PBC) in an individual in need thereof comprising administering a therapeutically effective amount of (R)-2-(7- (4-cyclopenty]-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
• PBC primary biliary cholangitis
• the present invention is directed to uses of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in the manufacture of a medicament for the treatment of primary biliary cholangitis (PBC) in an individual.
• PBC primary biliary cholangitis
• the present invention is directed to (/?)-2-(7-(4-cyclopentyl-3-
• Compound 1 (trifluoromethyl)benzyloxy)-l ,2,3,4-tetialiydrocyclopenta[bJindol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in the treatment of primary biliary cholangitis (PBC).
• PBC primary biliary cholangitis
• the present invention is directed to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC), wherein the medication is (/?)-2-(7-(4-cyclopentyl-3-
• a first number of daily units of a pharmaceutical composition comprising one or more doses of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein each dose is in an amount equivalent to about 1.5 mg or less of Compound 1 , and
• Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is in an amount equivalent to about 1.0 to about 2.5 mg of Compound 1.
• the methods provided herein are for the treatment of primary biliary cholangitis that has progressed to primary biliary cirrhosis. In some embodiments, the methods provided herein are for the prevention of primary biliary cirrhosis. In some embodiments, the methods provided herein are for delayed progression to primary biliary cirrhosis.
• ACS acute coronary syndrome
• ADL activities of daily living
• AE reverse event
• ALP alkaline phosphatase
• ALT aminotransferase
• AMA anti-mitochondrial antibodies
• ANA anti-nuclear antibodies
• AST aspartate aminotransferase
• SGOT AV
• AV atrio- ventricular
• bpm beats per minute
• CBC complete blood count
• CFR Code of Federal Regulations
• CI confidence interval
• CRF case report form
• CRP C-reactive protein
• CRO contract research organization
• D day
• DILI drug-induced liver injury
• ECG electrocardiogram
• ED50 half maximal dose
• eGFR estimated glomerular filtration rate
• ELISA enzyme-linked immunosorbent assay
• EOS end of study
• EOT end of treatment
• FDA Food and Drug
• FEV 1 forced expiratory volume
• FU follow up
• FVC forced vital capacity
• GCP Good Clinical Practice
• GGT gamma glutamyl transferase
• HBsAg hepatitis B surface antigen
• hCG human chorionic gonadotropin
• HCV hepatitis C virus
• HREC human research ethics committee (AUS)
• HIV human immunodeficiency virus
• HR heart rate
• ICH International Conference on Harmonization
• ICF informed consent form
• IEC Independent Ethics Committee
• the crystalline free-plate habit or morphology and processes useful in the preparation of a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)-benzyloxy)- 1 ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid are described in WO2016/209809.
• the plates were discovered from the novel synthetic methods and were shown to be thin hexagonal-like plates with two opposite sides of the plate being longer that the other sides (i.e., elongated hexagonal plate). However, due to the thin characteristic of the plates, a complete unbroken plate is rarely seen.
• microscopy is one of the more useful techniques to distinguish two crystalline habits or morphologies. This is particularly useful when 2 or more morphologies are associated with the same or substantially the same crystal phase as is the case with the L-arginine salt of Compound 1.
• specific surface can also be used to characterize a habit, such as the free-plates. Accordingly, the specific surface area values disclosed in the present invention have been obtained by means of a specific surface area analysis technique based on the BET (Brunauer, Emmett and Teller) theory, which is a well-accepted theory known in the art for the calculation of surface areas of solids by means of measuring their physical adsorption of gas molecules (see: Brunauer, S.; Emmett, P. H.; and Teller, E.; J. Am. Chem. Soc, 1938, 60, 309).
• BET Brunauer, Emmett and Teller
• the specific surface area values measured in the present invention have been calculated from the BET surface area plot obtained by measuring the quantity of nitrogen gas molecules adsorbed by a weighted amount of solid at different relative pressures (P/Po) within the range 0.05-0.3 (P/Po), at 77.3 K.
• the measurement of the adsorption of gas molecules was Carried out by means of a MicromeriticsTM TriStar II BET surface analyzer having the characteristics as set out below in Example 3. Namely, nitrogen gas was used for the adsorption measurement. The sample for each analysis was degassed at 25°C for 960 minutes under vacuum (i.e., 100 mm/Hg).
• the determination of the adsorption of nitrogen was measured at 77.3 K at eleven relative pressures (P/P 0 ) sufficiently dispersed within the range of about 0.05 to about 0.30 (i.e. eleven absolute pressures in the range of about 36 mm Hg to about 223 mm Hg relative to the saturated pressure at the time of measurement that ranged from about 738 mmHg to about 743 mmHg).
• One aspect of the present invention relates to a novel crystalline plate morphology of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid as described herein.
• One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (/?)-2-(7-(4-cyclopentyl-3-(trifluoromethy])benzyloxy)-l ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 20, at 8.2° ⁇ 0.2°, 16.4° + 0.2°, and 20.5° + 0.2". In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 20.5° + 0.2°, and 24.6° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 20, at 8.2° ⁇ 0.2°, 16.4° + 0.2°, 20.5° + 0.2°, and 24.6° ⁇ 0.2°. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° ⁇ 0.2°, 24.6° ⁇ 0.2°, and 28.8° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° ⁇ 0.2°, 24.6° ⁇ 0.2°, 28.8° ⁇ 0.2°, and 37.3° ⁇ 0.2°.
• the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208. 1 °C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C/minute.
• the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.0°C to 208.5°C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.5°C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.1 °C at a scan rate of 10°C/minute. In some
• the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.1 °C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 207.0°C to 208.1 °C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, the crystalhne free-plate habit has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH.
• DMS dynamic moisture sorption
• DMS dynamic moisture sorption
• One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (/?)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)- l ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a BET specific surface area of about 0.05 m 2 /g, about 0.1 m 2 /g, about 0.15 m 2 /g, about 0.2 m 2 /g, about 0.25 m 2 /g, about 0.3 m 2 /g, about 0.35 m 2 /g, about 0.4 m 2 /g, about 0.45 m 2 /g, about 0.5 m 2 /g, about 0.55 m 2 /g, about 0.6 m 2 /g, about 0.65 m /g, or about 0.7 m 2 /g to about 2.0 m 2 /g, about 2.5 m 2 /g
• the crystalline free-plate habit has a BET specific surface area of about 0.1 m 2 /g to about 5.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.1 m 2 /g to about 4.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.3 m 2 /g to about 4.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.5 m 2 /g to about 4.0 m 2 /g.
• the crystalline free-plate habit has a BET specific surface area of about 0.6 m 2 /g to about 4.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.3 m 2 /g to about 3.0 m /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.4 m 2 /g to about 2.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.5 m 2 /g to about 1.8 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.6 m ⁇ g to about 1.6 m /g.
• the crystalline free-plate habit has:
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• the crystalline free-plate habit has:
• a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C/minute;
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 1 208.5°C at a scan rate of 10°C/minute;
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• a pu der X-ray dittraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° + 0.2°, 20.5° ⁇ 0.2°, and 24.6° ⁇ 0.2°;
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• a BE T specific surface area of about 0.3 m 2 /g to about 3.0 m 2 /g.
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• the crystalline free-plate habit has: 1 ) a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° + 0.2°, and 24.6° ⁇ 0.2°;
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• the crystalline free-plate habit has:
• DMS dynamic moisture sorption
• One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° + 0.2°, 16.4° ⁇ 0.2°, and 20.5° + 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2(9, at 8.2° ⁇ 0.2°, 20.5° + 0.2°, and 24.6° + 0.2°. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2(9, at 8.2° ⁇ 0.2°, 16.4° + 0.2°, 20.5° ⁇ 0.2°, and 24.6° + 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° ⁇ 0.2°, 24.6° + 0.2°, and 28.8° + 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° + 0.2°, 24.6° + 0.2°, 28.8° ⁇ 0.2°, and 37.3° ⁇ 0.2°.
• One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C when scanned at 10°C per minute.
• the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.1°C at a scan rate of 10°C/minute.
• the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.1 °C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.0°C to 208.5°C at a scan rate of 10°C/minute.
• the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.5°C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.1°C at a scan rate of 10°C/minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 207.0°C to 208.1 °C at a scan rate of 10°C/minute.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2ft at 8.2° ⁇ 0.2°, 16.4° + 0.2°, and 20.5° ⁇ 0.2°. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2(9, at 8.2° ⁇ 0.2°, 20.5° + 0.2°, and 24.6° + 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2(9, at 8.2° + 0.2°, 16.4° ⁇ 0.2°, 20.5° ⁇ 0.2°, and 24.6° + 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° + 0.2°, 24.6° ⁇ 0.2°, and 28.8° + 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° ⁇ 0.2°, 24.6° ⁇ 0.2°, 28.8° ⁇ 0.2°, and 37.3° + 0.2°.
• One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluorornethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH.
• DMS dynamic moisture sorption
• the crystalline free-plate habit has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 20, at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, and 20.5° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2(9, at 8.2° + 0.2°, 20.5° ⁇ 0.2°, and 24.6° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° + 0.2°, and 24.6° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 (9, at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° ⁇ 0.2°, 24.6° + 0.2°, and 28.8° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 (9, at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° + 0.2°, 24.6° ⁇ 0.2°, 28.8° ⁇ 0.2°, and 37.3° + 0.2°.
• One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a BET specific surface area of about 0.1 m 2 /g to about 5.0 m 2 /g.
• the crystalline free-plate habit has a BET specific surface area of about 0.1 m /g to about 4.0 m /g.
• the crystalline free-plate habit has a BET specific surface area of about 0.3 m 2 /g to about 4.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.5 m 2 /g to about 4.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.6 m 2 /g to about 4.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.3 m 2 /g to about 3.0 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.4 m 2 /g to about 2.0 m 2 /g. In some embodiments,
• the crystalline free-plate habit has a BET specific surface area of about 0.5 m 2 /g to about 1.8 m 2 /g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.6 m 2 /g to about 1.6 nrVg. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, and 20.5° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2(9, at 8.2° ⁇ 0.2°, 20.5° + 0.2°, and 24.6° ⁇ 0.2°. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° + 0.2°, 20.5° + 0.2°, and 24.6° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2(9, at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° ⁇ 0.2°, 24.6° + 0.2°, and 28.8° ⁇ 0.2°.
• the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ⁇ , at 8.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 20.5° ⁇ 0.2°, 24.6° ⁇ 0.2°, 28.8° ⁇ 0.2°, and 37.3° + 0.2°.
• the present invention is directed to, inter alia, methods of treating primary biliary cholangitis (PBC) in an individual in need thereof comprising administering a therapeutically effective amount of (/?)-2-(7-(4-cyclopcntyl-3-(txifluoromethyI)benzyloxy)- 1 ,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically salt, solvate, or hydrate thereof.
• PBC primary biliary cholangitis
• the present invention is directed to uses of (/?)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in the manufacture of a medicament for the treatment of primary biliary cholangitis (PBC) in an individual.
• PBC primary biliary cholangitis
• the individual was previously treated with a therapeutically effective amount of ursodeoxycholic acid (UDCA).
• UDCA ursodeoxycholic acid
• the individual is currently treated with a therapeutically effective amount of ursodeoxycholic acid (UDCA).
• UDCA ursodeoxycholic acid
• the therapeutically effective amount of UDCA is about 10-20 mg/kg/day. In some embodiments, the therapeutically effective amount of UDCA is about 13-15 mg/kg/day.
• the therapeutically effective amount of UDCA is reduced when administered with Compound 1. In some embodiments, the therapeutically effective amount of UDCA is reduced to less than 15 mg/kg/day. In some embodiments, the therapeutically effective amount of UDCA is reduced to less than 13 mg kg/day. In some embodiments, the therapeutically effective amount of UDCA is reduced to less than 500 mg. In some embodiments, the therapeutically effective amount of UDCA is reduced to less than 500 mg per administration. In some embodiments, the therapeutically effective amount of UDCA is reduced to less than 250 mg. In some embodiments, the therapeutically effective amount of UDCA is reduced to less than 250 mg per administration .In some embodiments, the frequency of administration of UDCA is reduced.
• the administration of UDCA is reduced to four divided doses. In some embodiments, the administration of UDCA is reduced to three divided doses. In some embodiments, the administration of UDCA is reduced to two divided doses. In some embodiments, UDCA is administered four times daily. In some embodiments, UDCA is administered three times daily. In some embodiments, UDCA is administered twice daily.
• the therapeutically effective amount of Compound 1 is reduced when administered with UDCA. In some embodiments, the therapeutically effective amount of Compound 1 is reduced to less than 2 mg. In some embodiments, the therapeutically effective amount of Compound 1 is reduced to less than 1.5 mg. In some embodiments, the therapeutically effective amount of Compound 1 is reduced to less than 1 mg. In some embodiments, the frequency of administration of Compound 1 is reduced. In some embodiments, Compound 1 is administered once daily. In some embodiments, Compound 1 is administered every other day.
• the therapeutically effective amount of UDCA is about 100 mg to about 1000 mg. In some embodiments, the therapeutically effective amount of UDCA is about 250 mg to about 500 mg. In some embodiments, the therapeutically effective amount of UDCA is about 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, or 1000 mg. In some embodiments, the therapeutically effective amount of UDCA is about 250 mg. In some embodiments, the therapeutically effective amount of UDCA is about 250 mg. In some embodiments, the therapeutically effective amount of UDCA is about 250 mg. In some embodiment
• the therapeutically effective amount of UDCA is about 500 mg.
• the therapeutically effective amount of UDCA is administered in two to ten divided doses. In some embodiments, the therapeutically effective amount of UDCA is administered in two to four divided doses. In some embodiments, the therapeutically effective amount of UDCA is administered in two divided doses. In some embodiments, the therapeutically effective amount of UDCA is administered in three divided doses. In some embodiments, the therapeutically effective amount of UDCA is administered in four divided doses. In some embodiments, the therapeutically effective amount of UDCA is administered in five divided doses. In some embodiments, UDCA is administered four times daily. In some embodiments, UDCA is administered three times daily. In some embodiments, UDCA is administered twice daily.
• the therapeutically effective amount of UDCA is substantially the same amount (stable dose) for at least 6 months.
• the individual was previously treated with ursodeoxycholic acid (UDCA) and the individual had an inadequate response to UDCA.
• UDCA ursodeoxycholic acid
• the individual had an inadequate response to UDCA as determined by an alkaline phosphate (ALP) > 1.67 x upper limit of normal (ULN) for the individual.
• ALP alkaline phosphate
• UPN upper limit of normal
• the individual had an inadequate response after 6 months of treatment with
• the individual had an inadequate response after 6 months of treatment with UDCA and an alkaline phosphate (ALP) > 1.67 x upper limit of normal (ULN).
• ALP alkaline phosphate
• the treatment dose of UDCA was at least 13 mg/kg/day.
• the individual has at least one primary biliary cholangitis diagnosis criteria selected from the group consisting of:
• AMA anti-mitochondrial antibody
• ALP alkaline phosphate
• the individual has at least two primary biliary cholangitis diagnosis criteria selected from the group consisting of:
• AMA anti-mitochondrial antibody
• the individual has at least one of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• the individual has at least one. of the criteria selected from the group consisting of:
• ALP >1.67 x ULN but ⁇ 10 x ULN;
• the individual has at least one of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has at least one of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• TSH ⁇ 5.0 mU/L without clinical significant changes of free T3 and T4 levels; and Fibroscan® (transient elastography) ⁇ 10 kPa.
• the individual has at least two of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• TSH 5.0 mU/L without clinical significant changes of free T3 and T4 levels; and Fibroscan (transient elastography) ⁇ 10 kPa.
• the individual has at least two of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has at least three of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has at least three of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has al least four of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has at least four of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography ⁇ 10 kPa.
• the individual has at least five of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• TSH 5.0 mU/L without clinical significant changes of free T3 and T4 levels; and Fibroscan (transient elastography) ⁇ 10 kPa.
• the individual has at least five of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• TSH 5.0 mU/L without clinical significant changes of free T3 and T4 levels; and Fibroscan (transient elastography) ⁇ 10 kPa.
• the individual has at least six of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• TSH 5.0 mU/L without clinical significant changes of free T3 and T4 levels; and Fibroscan (transient elastography) ⁇ 10 kPa.
• the individual has at least six of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN; ALT and AST ⁇ 5 x ULN;
• Fibroscan transient elastography
• the individual has at least seven of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has at least seven of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has at least eight of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has at least eight of the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has all the criteria selected from the group consisting of:
• ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has all the criteria selected from the group consisting of: ALP > 1.67 x ULN but ⁇ 10 x ULN;
• Fibroscan transient elastography
• the individual has at least one additional condition selected from the group consisting of: pruritus, fatigue, osteoporosis, vitamin deficiencies, dry eyes and/or mouth, portal hypertension, and pain.
• the. therapeutically effective amount of Compound 1 or a
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is formulated as a capsule or tablet suitable for oral administration.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is formulated as a tablet suitable for oral administration.
• the individual is administered a titration dose of Compound 1 prior to the administering the therapeutically effective amount of Compound 1, wherein the titration dose is less than the therapeutically effective amount of Compound 1.
• the titration dose is less than about 2 mg of Compound 1.
• the titration dose is maintained until there are no significant changes in vital signs and/or EKG of the individual.
• the titration dose is maintained until the pulse rate > 55 bpm, systolic blood pressure (SBP) > 90, and diastolic blood pressure (DBP) > 55 mmHg in the individual.
• SBP systolic blood pressure
• DBP diastolic blood pressure
• the titration dose is maintained for no more than 14 days prior to administering the therapeutically effective amount of Compound 1.
• the titration dose comprises a first titration dose and a second titration dose, wherein the first titration dose is less than the second titration dose and each titration dose is less than the therapeutically effective amount of Compound 1.
• the first titration dose is in an amount equivalent to about 1 mg of Compound 1.
• the second titration dose is in an amount equivalent to about 1.5 mg of
• the first titration dose is in an amount equivalent to about 1 mg of Compound 1 and the second titration dose is in an amount equivalent to about 1.5 mg of Compound 1.
• the first titration duse is maintained for no more than 7 days prior to administering the second titration dose.
• the second titration dose is maintained for no more than 7 days prior to administering the therapeutically effective amount of Compound 1.
• the therapeutically effective amount of Compound 1 or a
• the therapeutically effective amount of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof is in an amount equivalent to about 1 mg to about 2 mg.
• pharmaceutically acceptable salt, hydrate, or solvate thereof is in an amount equivalent to about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75, or about 2 mg.
• the therapeutically effective amount of Compound 1 or a
• pharmaceutically acceptable salt, hydrate, or solvate thereof is in an amount equivalent to about 1 mg or about 2 mg.
• pharmaceutically acceptable salt, hydrate, or solvate thereof is in an amount equivalent to about 1 mg of Compound 1.
• the therapeutically effective amount of Compound 1 or a
• pharmaceutically acceptable salt, hydrate, or solvate, thereof is in an amount equivalent to 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, or 2 mg of Compound 1.
• the therapeutically effective amount of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof is in an amount equivalent to > 1 mg of Compound 1. In some embodiments, the therapeutically effective amount of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is in an amount equivalent to > 1.5 mg of Compound 1. In some embodiments, the therapeutically effective amount of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is in an amount equivalent to ⁇ 1 mg of Compound 1. In some embodiments, the therapeutically effective amount of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is in an amount equivalent to ⁇ 1.5 mg of Compound 1.
• the therapeutically effective amount of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof is in an amount equivalent to ⁇ 2 mg of Compound 1. In some embodiments, the therapeutically effective amount of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is no more than 1 mg, 1.5 mg, 2 mg, or 5 mg of Compound 1.
• the therapeutically effective amount of Compound 1 or a
• pharmaceutically acceptable salt, hydrate, or solvate thereof is in an amount equivalent to about 2 mg of Compound 1.
• the Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof is selected from: Compound 1 , a calcium salt of Compound 1, and an L-arginine salt of
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is an L-arginine salt of Compound 1.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is an anhydrous, non-solvated crystalline form of the L-arginine salt of Compound 1.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is a crystalline free-plate habit of the non-solvated L-arginine salt of Compound 1.
• the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is an anhydrous, non-solvated crystalline form of Compound 1.
• the method further comprises administering Compound 1 , or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a therapeutically effective amount of with a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and/or vitamin D supplement, and vitamin A, D, E and/or K supplement.
• a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and/or vitamin D supplement, and vitamin A, D, E and/or K supplement.
• Some embodiments of the present invention related to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC), wherein the medication is (R)-2-(7-(4-cyclopentyl-3-
• a first number of daily units of a pharmaceutical composition comprising one or more doses of
• Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is in an amount equivalent to about 1.0 to about 2.5 mg of Compound 1.
• the dose of the first number of daily units is in an amount equivalent to about 1 mg of Compound 1.
• the dose of the first number of daily units is in an amount equivalent to about 1.5 mg of Compound 1.
• the dose of the second number of daily units is in an amount equivalent to about 2 mg of Compound 1.
• the dose of the first number of daily units is in an amount equivalent to about 1 mg or 1.5 mg of Compound l and the dose of the second number of daily units is in an amount equivalent to about 2 mg of Compound 1.
• kits comprising a titration package according to any previous embodiment, and instructions indicating that the medication is to be administered to an individual in need of treatment of primary biliary cholangitis (PBC).
• PBC primary biliary cholangitis
• the individual is administered the therapeutically effective amount of Compound 1 once daily.
• the individual is administered the therapeutically effective amount of Compound 1 twice daily.
• the individual is administered the therapeutically effective amount of Compound 1 three times daily.
• the individual is administered the therapeutically effective amount of
• Compound 1 is administered without food.
• the individual has been identified as having impaired liver function prior to administration of the titration dose.
• Some embodiments relate to methods, further comprising:
• Some embodiments relate to methods, wherein impaired liver function of the individual is determined by a liver function test for at least one marker selected from: bilirubin, albumin, total protein, aminotransferase (ALT), aspartate aminotransferase (AST), creatinine kinase (CK), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP).
• a liver function test for at least one marker selected from: bilirubin, albumin, total protein, aminotransferase (ALT), aspartate aminotransferase (AST), creatinine kinase (CK), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP).
• One aspect of the present invention relates to methods of treating an individual in need thereof with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid (Compound 1) comprising:
• the at least one biomarker is selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate transaminase (AST); (vi) gamma-glutamyl transferase (GGT); (vii) antimitochondrial antibodies (AMA); (viii) Golgi protein 73 (GP73); (viii) bile acid; (x) complement factor 4 (C4); (xi) IgG; and (xii) IgM.
• the at least one biomarker is selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate
• One aspect of the present invention relates to methods of treating an individual in need thereof with (i?)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid (Compound 1) comprising:
• the at least one biomarker is selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate transaminase (AST); (vi) gamma-glutamyl transferase (GGT); (vii) antimitochondrial antibodies (AMA); (viii) Golgi protein 73 (GP73); (viii) bile acid; (x) complement factor 4 (C4); (xi) IgG; and (xii) IgM.
• the at least one biomarker is selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate
• One aspect of the present invention relates to methods of treating an individual in need thereof with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid (Compound 1) comprising:
• step (d) ⁇ (i) continuing administration of Compound 1 if the second level of the at least one biomarker in step (c) is less than or about equal to the corresponding first level of the at least one biomarker in step (a); or
• step (ii) discontinuing administration of Compound 1 if the second level of the at least one biomarker in step (c) is greater than the corresponding first level of the at least one biomarker in step (a); wherein the at least one biomarker is selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate transaminase (AST); (vi) gamma-glutamyl transferase (GGT); (vii) antimitochondrial antibodies (AMA); (viii) Golgi protein 73 (GP73); (viii) bile acid; (x) complement factor 4 (C4); (xi) IgG; and (xii) IgM.
• the at least one biomarker is selected from the group consisting of: (i) anti-gp210; (
• the individual has primary biliary cholangitis (PBC).
• PBC primary biliary cholangitis
• the individual has fatigue, pruritus, eye dryness, and/or Sjogren's syndrome (SS). In some embodiments, the individual has fatigue.
• SS Sjogren's syndrome
• the individual has pruritus.
• the individual has eye dryness.
• the individual has Sjogren's syndrome (SS).
• SS Sjogren's syndrome
• the second level of the at least one biomarker in step (c) is 2% less, 5% less, 10% less, 12% less, 15% less, 17% less, 20% less, 22% less, 25% less, 30% less, 35% less, 40% less, 45% less, 50% less, or > 50% less than the corresponding first level of the at least one biomarker in step (a).
• the at least one biomarker is two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve biomarkers selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate transaminase (AST); (vi) gamma-glutamyl transferase (GGT); (vii) antimitochondrial antibodies (AMA); (viii) Golgi protein 73 (GP73); (viii) bile acid; (x) complement factor 4 (C4); (xi) IgG; and (xii) IgM.
• biomarkers selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (i
• the at least one biomarker in step (c) is two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve biomarkers selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate transaminase (AST); (vi) gamma-glutamyl transferase (GGT); (vii) antimitochondrial antibodies (AMA); (viii) Golgi protein 73 (GP73); (viii) bile acid; (x) complement factor 4 (C4); (xi) IgG; and (xii) IgM.
• biomarkers selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hs
• One aspect of the piesent Invention relates to methods of treating fatigue in an individual in need thereof comprising administering a therapeutically effective amount of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penla[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically salt, solvate, or hydrate thereof.
• One aspect of the present invention relates to methods of treating fatigue in an individual with primary biliary cholangitis (PBC) comprising administering a therapeutically effective amount of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically salt, solvate, or hydrate thereof.
• PBC primary biliary cholangitis
• One aspect of the present invention relates to methods of treating pruritus in an individual in need thereof comprising administering a therapeutically effective amount of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically salt, solvate, or hydrate thereof.
• One aspect of the present invention relates to methods of treating pruritus in an individual with primary biliary cholangitis (PBC) comprising administering a therapeutically effective amount of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1 ), or a pharmaceutically salt, solvate, or hydrate thereof.
• PBC primary biliary cholangitis
• One aspect of the present invention relates to methods of treating eye dryness in an individual in need thereof comprising administering a therapeutically effective amount of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically salt, solvate, or hydrate thereof.
• One aspect of the present invention relates to methods of treating eye dryness in an individual with primary biliary cholangitis (PBC) comprising administering a therapeutically effective amount of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1 ), or a pharmaceutically salt, solvate, or hydrate thereof.
• PBC primary biliary cholangitis
• One aspect of the present invention relates to methods of treating Sjogren's syndrome (SS) in an individual in need thereof comprising administering a therapeutically effective amount of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically salt, solvate, or hydrate thereof.
• SS Sjogren's syndrome
• One aspect of the present invention relates to methods of treating Sjogren's syndrome (SS) in an individual with primary biliary cholangitis (PBC) comprising administering a therapeutically effective amount of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol- 3-yl)acetic acid (Compound 1), or a pharmaceutically salt, solvate, or hydrate thereof.
• One aspect of the present invention relates to methods of treating an individual in need thereof with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l ,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid (Compound 1) comprising:
• the at least one biomarker is selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate transaminase (AST); (vi) gamma-glutamyl transferase (GGT); (vii) antimitochondrial antibodies (AMA); (viii) Golgi protein 73 (GP73); (viii) bile acid; (x) complement factor 4 (C4); (xi) IgG; and (xii) IgM.
• the at least one biomarker is selected from the group consisting of: (i) anti-gp210; (ii) anti-splOO; (iii) serum high sensitivity C-reactive protein (hsCRP); (iv) alanine transaminase (ALT); (v) aspartate
• modifying the administration of Compound 1 comprises increasing the amount of Compound 1.
• modifying the administration of Compound 1 comprises decreasing the amount of Compound 1.
• the individual has been administered Compound 1 prior to modified administration.
• the amount of UDCA is about 13 mg/kg/day to about 15 mg/kg/day. In some embodiments, the UDCA is administered in two to four divided doses.
• the amount of UDCA is about 250 mg or about 500 mg. In some embodiments, the amount or frequency of administration of UDCA is reduced when administered with Compound 1.
• the amount or frequency of administration of Compound 1 is reduced when administered with UDCA.
• a further aspect of the present invention pertains to pharmaceutical compositions comprising one or more compounds as described herein and one or more pharmaceutically acceptable carriers. Some embodiments pertain to pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier.
• Some embodiments of the present invention include a method of producing a pharmaceutical composition comprising admixing at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier.
• Formulations may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, forming the resulting mixture into a desired shape.
• Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions and syrups.
• the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives and flavorings and colorants may be added to the liquid preparations.
• Parenteral dosage forms may be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.
• a compound of the present invention can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically acceptable carriers, outside those mentioned herein, arc known in the an; for example, see Remington, The Science and Practice of Pharmacy, 20 lh Edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro et al.)
• a compound of the invention may, in an alternative use, be administered as a raw or pure chemical, it is preferable however to present the compound or active ingredient as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier.
• the invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt, solvate, hydrate or derivative thereof together with one or more pharmaceutically acceptable carriers thereof and/or prophylactic ingredients.
• the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.
• Transdermal patches dispense a drug at a controlled rate by presenting the drug for absorption in an efficient manner with a minimum of degradation of the drug.
• transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner.
• the compounds of the invention may thus be placed into the form of pharmaceutical formulations and unit dosages thereof and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, gels or capsules filled with the same, all for oral use; in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
• Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
• the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid.
• the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
• dosage units are capsules, tablets, powders, granules or suspensions, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethyl- cellulose; and with lubricants such as talc or magnesium stearate.
• the active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable pharmaceutically acceptable carrier.
• compositions specifically as S 1P1 receptor modulators.
• active ingredient is defined in the context of a "pharmaceutical composition” and is intended to mean a component of a pharmaceutical composition that provides the primary pharmacological effect, as opposed to an "inactive ingredient” which would generally be recognized as providing no pharmaceutical benefit.
• the dose when using the compounds of the present invention can vary and as is customary and known to the physician, it is to be tailored to the individual conditions in each individual case.
• Representative doses of the present invention include, but are not limited to, about 1 mg to about 5 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4,75 mg, and about 5 mg. Multiple doses may be administered during the day, especially when relatively large amounts are deemed to be needed, for example 2, 3 or 4 doses.
• the amount of active ingredient or an active salt, solvate or hydrate derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the individual and will ultimately be at the discretion of the attendant physician or clinician. Representative factors include the type, age, weight, sex, diet and medical condition of the individual, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, whether an acute or chronic disease state is being treated or prophylaxis is conducted or whether further active compounds are administered in addition to the compounds of the present invention and as part of a drug combination.
• the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety factors including those cited above.
• the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimens outside these typical ranges can be tested and, where appropriate, may be used in the methods of this invention.
• the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate interval , for example, as 2, 3, 4 or more sub-doses per day.
• the sub-dose itself may be further divided, e,g., into a number of discrete loosely spaced administrations.
• the daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4 part administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
• the suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both.
• Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersible granules.
• a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or encapsulating materials.
• the carrier is a finely divided solid which is in a mixture with the finely divided active component.
• the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desired shape and size.
• the powders and tablets may contain varying percentage amounts of the active compound.
• a representative amount in a powder or tablet may be from 0.5 to about 90 percent of the active compound.
• Suitable carriers for powders and tablets include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter and the like.
• the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
• cachets and lozenges are included. Tablets, powders, capsules, pills, cachets and lozenges can be used as solid forms suitable for oral administration.
• a low melting wax such as an admixture of fatty acid glycerides or cocoa butter
• the active component is dispersed homogeneously therein (e.g., by stirring).
• the molten homogenous mixture is then poured into convenient sized molds, allowed to cool and thereby to solidify.
• Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
• Liquid form preparations include solutions, suspensions and emulsions, for example, water or water-propylene glycol solutions.
• parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
• injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
• Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• any bland fixed oil may be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid find use in the preparation of injectables.
• the compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
• the pharmaceutical compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
• the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
• Aqueous formulations suitable for oral use can be prepared by dissolving or suspending the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents, as desired.
• Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
• viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
• solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
• liquid forms include solutions, suspensions and emulsions.
• These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents and the like.
• the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
• Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
• Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
• Formulations suitable for topical administration in the mouth include lozenges comprising the active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
• Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
• the formulations may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the individual administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
• Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant.
• aerosols ⁇ e.g., nasal aerosols, by inhalation
• this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler.
• Pharmaceutical forms for administration of the compounds of the present invention as an aerosol can be prepared by processes well known to the person skilled in the art.
• Solutions or dispersions of the compounds of the present invention or a pharmaceutically acceptable salt, solvate, hydrate or derivative thereof in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives (e.g., benzyl alcohol or other suitable preservatives), absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others and, if appropriate, customary propellants (e.g., carbon dioxide, CFCs, such as, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane and the like).
• the aerosol may conveniently also contain a surfactant such as lecithin.
• the dose of drug may be controlled by provision of a metered valve.
• the compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.
• the active ingredients may be provided in the form of a dry powder (e.g., a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP)3 ⁇ 4
• a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP)3 ⁇ 4
• the powder carrier will form a gel in the nasal cavity.
• the powder composition may be presented in unit dose form (e.g., capsules, cartridges) as for gelatin or blister packs from which the powder may be administered by means of an inhaler.
• the pharmaceutical preparations are preferably in unit dosage forms.
• the preparation is subdivided into unit doses containing appropriate quantities of the active component.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules and powders in vials or ampoules.
• the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
• compositions are tablets or capsules for oral administration.
• compositions are liquids for intravenous administration.
• the compounds according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
• Representative acids include, but are not limited to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfiric, tartaric, oxalic, p-toluenesulfonic and the like, such as those pharmaceutically acceptable salts listed by Berge et al., Journal of Pharmaceutical Sciences, 66: 1-19 (1977), incorporated herein by reference in its entirety.
• the acid addition salts may be obtained as the direct products of compound synthesis.
• the free base may be dissolved in a suitable solvent containing the appropriate acid and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
• the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
• Pro-drugs refers to compounds that have been modified with specific chemical groups known in the art and that when administered into an individual undergo biotransformation to give the parent compound. Pro-drugs can thus be viewed as compounds of the invention containing one or more specialized non-toxic protective groups used in a transient manner to alter or to eliminate a property of the compound. In one general aspect, the "pro-drug” approach is utilized to facilitate oral absorption. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems Vol. 14 of the A.C.S.
• Some embodiments of the present invention include a method of producing a pharmaceutical composition for "combination-therapy" comprising admixing at least one compound according to any of the compound embodiments disclosed herein, together with at least one known pharmaceutical agent as described herein and a pharmaceutically acceptable carrier.
• a phase I/II, open-label, single arm, proof-of-concept study is performed to evaluate the safety, tolerability and efficacy of Compound 1 in individuals with primary biliary cholangitis (PBC).
• PBC primary biliary cholangitis
• the study is conducted in individuals aged 18 to 80 years old (inclusive) who have PBC and an inadequate response to ursodeoxycholic acid (UDCA) and are on a stable dose of UDCA for at least 6 months prior to screening.
• the trial includes an initial pilot study to assess pharmacokinetics and tolerability for up to ten individuals.
• Primary objectives include efficacy (i.e., changes in ALP levels from baseline), safety and tolerability of Compound 1 in individuals with PBC over a 24-week treatment period.
• Exploratory objectives include assessment of the following: 1) the pharmacokinetic (PK) profile of Compound 1 in individuals with PBC; 2) the pharmacodynamic (PD) response (lymphocyte counts and suhsets thereof) and changes in antinuclear antibodies (ANA) (anti-gp210 and anti-splOO) and other exploratory biomarkers over a 24-week treatment period; 3) serum high sensitivity C-reactive protein (hsCRP), alanine transaminase (ALT), aspartate transaminase (AST), ganirna-glutamyl transferase (GGT), antimitochondrial antibodies (AMA), Golgi protein 73 (GP73), complement factor 4 (C4), bile acid, total IgG, total IgM, over a 24-week treatment period; 4) complete blood count (CBC); 5) quality of life (QoL) and incidence of pruritus and/or fatigue over a 24-week treatment period; 6) safety, tolerability and efficacy of
• a four-week pilot study is run to assess safety and tolerability, including PK and maximum tolerated dose, in up to 10 individuals before proceeding with the remainder of the clinical trial. Individuals are admitted to the clinic on Day -1 and stay until Day 3. Vital signs and EKG changes are monitored extensively during this time. I dividuals have abbreviated PK sampling pre-dose (baseline) and at 0.5, 1, 2, 4, 6, 8, and 12 hours after dosing on Day 1, and 6 hours post-dosing on Days 2 and 3. Individuals receive 1 mg of Compound 1 (PO, QD) on Days 1, 2, and 3. If 1 mg of Compound 1 is well tolerated and there are no clinically significant changes in vital signs and EKG, the 1 mg dose level is maintained and the individual is discharged on Day 3. If 1 mg is not tolerated, then treatment is stopped if any of the following findings are made during treatment:
• ALT/AST >3 x baseline level and >ULN; or • Total bilirubin >2 x baseline level and >1.5 mg/dL.
• the 1 mg dose level may be increased to 2 mg at Week 4 based on the individual's safety and PK data. Individuals with dose escalation on Week 4 have an additional PK sampling, and vital signs and ECG monitoring are performed every 30 minutes until at least 6 hours post dosing. Dosage is maintained at 2 mg QD if possible, but may return to 1 mg QD if deemed necessary.
• Dosage is maintained at 2 mg QD if possible, but may return to 1 mg QD if deemed necessary.
• Safety and tolerability are assessed by monitoring adverse events and vital signs, ECG, and blood tests. Individuals return to the study site at Weeks 1 , 2, 4, 8, 12, 16, 20, and 24 for examinations as described in Schedule of Procedures and Visits ( Figures 2 to 6).
• the last dose of Compound 1 is administered one day before the end of the 24-week treatment period.
• ALP, GGT, ALT/AST, bilirubin (total and direct), PT/INR, albumin, lipid panel, and total serum IgG/IgM as well as a PBC-40 questionnaire and a 5-D Pruritus scale VAS are measured during the study period.
• alkaline phosphate (ALP) > 1.5 x ULN for at least 6 months;
• ALP > 1.67 x ULN but ⁇ 10 x ULN
• Fibroscan® transient elastography
• QuantiFERON ® test this criterion may be assessed on a case by case basis with medical monitor.
• a positive diagnostic TB test at screening defined as a positive QuantiFERON ® test or 2 successive indeterminate QuantiFERON ® tests.
• B cell or T cell targeted therapies such as natalizumab, rituximab, abatacept, ustekinurnab
• B cell or T cell targeted therapies such as natalizumab, rituximab, abatacept, ustekinurnab
• OCA obetichulic acid
• fibrates including bezafibrate
• Drugs not allowed per the UDCA prescribing information agents used for the treatment of any condition listed in the exclusionary enrollment criteria within 30 days prior to Day 1 ; Exposure to B cell or T cell targeted therapies (such as natalizumab, rituximab, abatacept, ustekinurnab) within 30 days prior to Day 1 and during the study; azathioprine, colchicine, or methotrexate within 30 days prior to Day 1 and during the study; fibrates (including bezafibrate) within 30 days prior to Day 1 and during the study; treatment with OCA within 30 days prior to Day 1 and during the study; immunosuppressive, immunomodulating agents such as 5-ASA, azathioprine, colchicine, or methotrexate due to the potential impact on ALP; use of moderate to strong inhibitors of CYP2C9 (e.g., amiodarone, felbamate, fluconazole, miconazole, piperine, diosmin, disulfiram..
• CYP2C9 e.g., amiodarone, felbamate, fluconazole, miconazole, piperine, diosmin, disulfiram, fluvastatin, fluvoxamine, voriconazole
• VZV varicella zoster virus
• FEVl Abnormal forced expiratory volume
• FVC forced vital capacity
• PML progressive multifocal leukoencephalopathy
• Example 3 BET (Brunauer, Emmett, and Teller) Specific Surface Area Method (Plate Habit)
• the specific surface areas for crystalline free-plate habit of the non-solvated L-arginine salt of Compound 1 were determined by physical adsorption of nitrogen gas on the surface of the sample from each lot using the well-established technique based on the Brunauer, Emmet.t, and Teller theory.
• the BET surface areas for the samples were measured by Micromeritics Pharmaceutical Services using a MicromeriticsTM TriStar II BET surface area analyzer (MicroActive for TriStar II Plus 2.02 SoftwareTM). The samples were degassed at 25°C for 960 minutes under vacuum (i.e., 100 mm/Hg). The determination of the adsorption of N? at 77.3 K was measured using a BET surface area eleven-point method with relative pressures in the range of about 0.05 to about 0.3 (P/Po) for a weighed amount of each sample, see Table 1 beluw. The analysis was performed per IS09277.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (9)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (1)

Family

ID=61873875

Family Applications (1)

Country Status (10)

Cited By (9)

Families Citing this family (2)

Citations (3)

Family Cites Families (445)

• 2018
  • 2018-02-16 MX MX2019009841A patent/MX2019009841A/es unknown
  • 2018-02-16 CN CN201880024045.9A patent/CN110520124A/zh active Pending
  • 2018-02-16 US US16/486,464 patent/US11534424B2/en active Active
  • 2018-02-16 EP EP18715275.6A patent/EP3582772A1/en not_active Withdrawn
  • 2018-02-16 MA MA047504A patent/MA47504A/fr unknown
  • 2018-02-16 CA CA3053418A patent/CA3053418A1/en active Pending
  • 2018-02-16 KR KR1020197026594A patent/KR20190116416A/ko not_active Withdrawn
  • 2018-02-16 WO PCT/US2018/000091 patent/WO2018151873A1/en not_active Ceased
  • 2018-02-16 AU AU2018220521A patent/AU2018220521A1/en not_active Abandoned
  • 2018-02-16 JP JP2019544629A patent/JP2020507611A/ja active Pending
• 2022
  • 2022-11-18 US US17/990,068 patent/US20230149353A1/en active Pending

Patent Citations (3)

Non-Patent Citations (16)

Also Published As

Similar Documents